Therefore, in this study, we focused on the PTs, the primary target of SGLT2is, to analyze the MR-mediated effects of Ald on K+ excretion, and Na+ reabsorption in the PTs to clarify the therapeutic potential of combining MRBs and SGLT2i for managing DKD. This evidence concerns the gene NR3C2 and diabetic kidney disease.